Trial Profile

TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Letrozole
Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms HELEX

12 Mar 2025 Planned End Date changed from 1 Jan 2024 to 1 Jan 2026.
17 May 2023 Results (TBCRC023 and PAMELA studies) hypothesizing that a multiparameter classifier can identify patients with HER2 "addicted" tumors who may benefit from a chemotherapy-sparing strategy published in the Clinical Cancer Research
15 May 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com